Current Report Filing (8-k)
April 14 2014 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
April 10, 2014
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Nevada |
001-15697
|
22-3542636
|
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
165 Ludlow Avenue, Northvale NJ 07647
(Address of principal
executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01. | Entry into a Material Definitive Agreement. |
| Item 3.02 | Unregistered Sales of Equity Securities |
Lincoln Park Transaction.
On April 10, 2014, we entered into a purchase agreement (the
“Purchase Agreement”), together with a registration rights agreement (the “Registration Rights Agreement”),
with Lincoln Park Capital Fund, LLC (“Lincoln Park”).
Under the terms and subject to the conditions of the Purchase
Agreement, the Company has the right to sell to and Lincoln Park is obligated to purchase up to $40 million in shares of the Company’s
common stock (“Common Stock”), subject to certain limitations, from time to time, over the 36-month period commencing
on the date that a registration statement, which the Company agreed to file with the Securities and Exchange Commission (the “SEC”)
pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith
is filed. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 500,000
shares of Common Stock on any business day, provided that at least one business day has passed since the most recent purchase,
increasing to up to 800,000 shares, depending upon the closing sale price of the Common Stock (such purchases, “Regular Purchases”).
However, in no event shall a Regular Purchase be more than $760,000. The purchase price of shares of Common Stock related to the
future funding will be based on the prevailing market prices of such shares at the time of sales, but in no event will shares be
sold to Lincoln Park on a day the Common Stock closing price is less than the floor price as set forth in the Purchase Agreement.
In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a Regular
Purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the Purchase Agreement. The
Company’s sales of shares of Common Stock to Lincoln Park under the Purchase Agreement are limited to no more than the number
of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more
than 9.99% of the then outstanding shares of the Common Stock.
In connection with the Purchase Agreement, the Company issued
to Lincoln Park 1,928,641 shares of Common Stock and is required to issue up to 1,928,641 additional shares of Common Stock pro
rata as the Company requires Lincoln Park to purchase the Company’s shares under the Purchase Agreement over the term of
the agreement. Lincoln Park represented to the Company, among other things, that it was an “accredited investor” (as
such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)),
and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(2) under the Securities
Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration
requirements.
The Purchase Agreement and the Registration Rights Agreement
contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification
rights and obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or
penalty. Actual sales of shares of Common Stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors
to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Common
Stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. There are
no trading volume requirements or restrictions under the Purchase Agreement. Lincoln Park has no right to require any sales by
the Company, but is obligated to make purchases from the Company as it directs in accordance with the Purchase Agreement. Lincoln
Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares.
The net proceeds under the Purchase Agreement to the Company
will depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. The Company expects that
any proceeds received by the Company from such sales to Lincoln Park under the Purchase Agreement will be used for general corporate
purposes and working capital requirements.
The foregoing descriptions of the Purchase Agreements and the
Registration Rights Agreement are qualified in their entirety by reference to the full text of the Purchase Agreement and the Registration
Rights Agreement, copies of which are attached hereto as Exhibit 10.1 and 10.2, respectively, and each of which is incorporated
herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were made only
for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may
be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged
between the parties in connection with execution of the agreements.
| Item 9.01. | Financial Statements and Exhibits. |
(c) Exhibits:
|
10.1 |
Common Stock Purchase Agreement, dated April 10, 2014
|
|
10.2 |
Registration Rights Agreement, dated April 10, 2014
|
|
99.1
|
Press Release dated April 14, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Dated: April 11, 2014 |
ELITE PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/ Nasrat Hakim |
|
|
Nasrat Hakim |
|
|
Chief Executive Officer |
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024